125 related articles for article (PubMed ID: 38385970)
1. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database.
Lu HJ; Hsieh MC; Wang HM; Hsieh JC; Yen CJ; Wu SY; Huang HC; Wang HC; Chu PY; Chen TH; Chien CY; Huang TL; Chang YF; Hua CH; Lien MY; Chen JP; Lu WC; Lin JC; Wang CC; Liu YC; Yang MH; Lou PJ
Head Neck; 2024 May; 46(5):1063-1073. PubMed ID: 38385970
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
4. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
5. A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis.
Zhu RQ; Zhang YM; Luo XY; Shen WY; Zhu HY
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1467-1478. PubMed ID: 36316576
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
[TBL] [Abstract][Full Text] [Related]
7. Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma.
Berzenji D; Sewnaik A; Keereweer S; Monserez DA; Verduijn GM; van Meerten E; Mast H; Mureau MAM; van der Lugt A; Koljenovic S; Dronkers EAC; Baatenburg de Jong RJ; Hardillo JA
Oral Oncol; 2021 Aug; 119():105356. PubMed ID: 34034098
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
9. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study.
Wang HC; Liu PL; Lo PC; Chang YT; Chan LP; Yeh TJ; Hsiao HH; Cho SF
PeerJ; 2020; 8():e9862. PubMed ID: 32974098
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
[TBL] [Abstract][Full Text] [Related]
12. Distant metastasis in head and neck squamous cell carcinoma variants: A population-based study.
Takenaka Y; Uno A; Tanaka H; Takemoto N; Inohara H
Head Neck; 2023 Apr; 45(4):882-889. PubMed ID: 36811303
[TBL] [Abstract][Full Text] [Related]
13. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
[TBL] [Abstract][Full Text] [Related]
15. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy?
Spector ME; Chinn SB; Rosko AJ; Worden FP; Ward PD; Divi V; McLean SA; Moyer JS; Prince ME; Wolf GT; Chepeha DB; Bradford CR
Laryngoscope; 2012 Jul; 122(7):1507-11. PubMed ID: 22460441
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract][Full Text] [Related]
18. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
19. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
Yokota T; Ota Y; Fujii H; Kodaira T; Shimokawa M; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
Int J Clin Oncol; 2021 Feb; 26(2):316-325. PubMed ID: 33125596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]